Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.
Dr. Reddy’s Laboratories has announced that its Board of Directors will meet on January 23, 2025, to review and approve the company’s unaudited financial results for the quarter and nine months ending December 31, 2024. Additionally, the company has imposed a trading window closure for its securities from December 25, 2024, to January 25, 2025, in compliance with insider trading regulations, signifying a period during which stakeholders should refrain from trading company shares.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a global pharmaceutical company based in Hyderabad, India, engaged in providing affordable and innovative medicines. The company operates in the pharmaceutical industry, focusing on generic medicines, active pharmaceutical ingredients, and proprietary products.
YTD Price Performance: 11.00%
Average Trading Volume: 1,063,136
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.17B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
